Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Human Papillomavirus (HPV) DNA testing based Cervical Cancer Screening and triage with CINtec PLUS Cytology test in HPV positive women in Bogalay Township, Ayeyarwady Region, Myanmar
    Shwe, Mu Mu
    Thwe, Khin Kay
    Hlaing, Su Su
    Aye, Lynn Pa Pa
    Aung, Kham Mo
    Lwin, Nu
    Tun, Win Maw
    Htun, Zaw Than
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2021, 30 (07)
  • [32] Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial
    Smith, Laurie
    van Niekerk, Dirk
    Coldman, Andrew
    Krajden, Mel
    Franco, Eduardo L.
    Ogilvie, Gina
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2016, 38 (08) : 723 - 726
  • [33] Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option.: Experience from the LAMS Study
    Longatto-Filho, A.
    Roteli-Martins, C.
    Hammes, L.
    Etlinger, D.
    Pereira, S. M. Miranda
    Erzen, M.
    Branca, M.
    Naud, P.
    Derchain, S. F. M.
    Sarian, L. O.
    Matos, J.
    Gontijo, R.
    Lima, T.
    Maeda, M. Y. S.
    Tatti, S.
    Syrjanen, S.
    Syrjanen, K.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2008, 29 (04) : 327 - 332
  • [34] Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology
    Thomsen, Louise T.
    Kjaer, Susanne K.
    Munk, Christian
    Ornskov, Dorthe
    Waldstrom, Marianne
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (03) : 394 - 402
  • [35] The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis
    Felix, Juan C.
    Lacey, Michael J.
    Miller, Jeffrey D.
    Lenhart, Gregory M.
    Spitzer, Mark
    Kulkarni, Rucha
    JOURNAL OF WOMENS HEALTH, 2016, 25 (06) : 606 - 616
  • [36] Human Papillomavirus (HPV) Infection in Women Participating in Cervical Cancer Screening from 2006 to 2010 in Shenzhen City, South China
    Wang, Yue-Yun
    Li, Li
    Wei, Sheng
    Peng, Ji
    Yuan, Shi-Xin
    Xie, Jian-Sheng
    Liu, Zhi-Hua
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (12) : 7483 - 7487
  • [37] Initial results of a population-based cervical cancer screening program using HPV testing in 1 million women
    Gultekin, M.
    Karaca, M. Zayifoglu
    Kucukyildiz, I.
    Dundar, S.
    Boztas, G.
    Turan, S. H.
    Hacikamiloglu, E.
    Murtuza, K.
    Keskinkilic, B.
    Sencan, I.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 115 - 116
  • [38] COST-EFFECTIVENESS ANALYSIS OF CERVICAL CANCER SCREENING WITH SELF-SAMPLING FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN TAIWAN
    Tsai, B. C.
    Chow, I. H. I.
    Liao, C. H.
    You, S. L.
    Tang, C. H.
    Pwu, R. F.
    VALUE IN HEALTH, 2012, 15 (07) : A656 - A657
  • [39] Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study
    Cox, J. Thomas
    Castle, Phillip E.
    Behrens, Catherine M.
    Sharma, Abha
    Wright, Thomas C., Jr.
    Cuzick, Jack
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (03) : 184.e1 - 184.e11
  • [40] De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening
    Hahn, Erin E.
    Munoz-Plaza, Corrine
    Altman, Danielle E.
    Hsu, Chunyi
    Cannizzaro, Nancy T.
    Ngo-Metzger, Quyen
    Wride, Patricia
    Gould, Michael K.
    Mittman, Brian S.
    Hodeib, Melissa
    Tewari, Krishnansu S.
    Ajamian, Lena H.
    Eskander, Ramez N.
    Tewari, Devansu
    Chao, Chun R.
    IMPLEMENTATION SCIENCE COMMUNICATIONS, 2021, 2 (01):